Net Loss per Share

12 Months Ended

Dec. 31, 2019

Basic and diluted net loss per share was calculated as follows:


	Year Ended December 31,
(in thousands, except share and per share amounts)	2019		2018		2017
Numerator:
Net loss	$	(192,256)	$	(99,854)	$	(50,284)
Denominator:
Weighted average common shares outstanding—basic and diluted	42,869,058		35,390,480		16,792,179
Net loss per share—basic and diluted	$	(4.48)	$	(2.82)	$	(2.99)

On October 2, 2017, in connection with the closing of the IPO, all outstanding convertible preferred shares of Deciphera Pharmaceuticals, LLC were exchanged for shares of common stock of Deciphera Pharmaceuticals, Inc. upon the Conversion. For additional information, please read Note 1, Nature of the Business and Basis of Presentation, to these consolidated financial statements. In addition, because the Company had a net loss in each of the periods presented, diluted net loss per share attributable to common shareholders has not been presented as the effect of including common share equivalents in the calculations would have had an anti-dilutive impact.

The Company did not have any common shares outstanding during the period from January 1, 2017 through the closing of its initial public offering on October 2, 2017. Because the Series A convertible preferred shares represented the most subordinate share class outstanding during that period, in determining weighted average common shares outstanding for purposes of calculating net loss per share for periods prior to the IPO, the Company utilized Series A convertible preferred shares. Such shares have also been retrospectively adjusted to give effect to the exchange of Series A convertible preferred shares into shares of common stock upon the Conversion.

Common Stock Equivalents

The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:


	As of December 31,
	2019	2018	2017
Options to purchase common stock	6,750,939	5,787,151	4,598,352
Unvested time-based restricted common stock units	99,500	25,000	—
Unvested performance-based restricted common stock units	57,400	—	—
Total	6,907,839	5,812,151	4,598,352